sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversering av nevromuskulær blokade indusert av rocuronium eller vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
tresuvi 10 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 10 mg/ ml
tresuvi 1 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 1 mg/ ml
tresuvi 2.5 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 2.5 mg/ ml
tresuvi 5 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 5 mg/ ml
raploc 300 mg
amomed pharma gmbh - landiololhydroklorid - pulver til infusjonsvæske, oppløsning - 300 mg
oxlumo
alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - andre alimentary tract and metabolism products, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
amvuttra
alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andre nervesystemet narkotika - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
sunlenca
gilead sciences ireland unlimited company - lenacapavir sodium - hiv-infeksjoner - antivirale midler til systemisk bruk - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 og 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 og 5.